checkAd

     111  0 Kommentare Merck cites EnWave’s REV Technology as a Faster, Viable Drying Alternative to Vial-Based Lyophilization for Vaccines and Biologics - Seite 2


    EnWave Corporation, a Vancouver-based advanced technology company, has developed a Radiant Energy Vacuum (“REV”) – an innovative, proprietary method for the precise dehydration of organic materials. EnWave has further developed patent-pending methods for uniformly drying and decontaminating cannabis through the use of REV technology, shortening the time from harvest to high-quality, marketable cannabis products.

    REV technology’s commercial viability has been demonstrated and is growing rapidly across several market verticals in the food, and pharmaceutical sectors, including legal cannabis. EnWave’s strategy is to sign royalty-bearing commercial licenses with innovative, disruptive companies in multiple verticals for the use of REV technology. The company has signed over forty royalty-bearing licenses to date in twenty countries world-wide. In addition to these licenses, EnWave established a Limited Liability Corporation, NutraDried Food Company, LLC, to manufacture, market and sell all-natural dairy snack products in the United States, including the Moon Cheese brand.

    EnWave has introduced REV as a disruptive dehydration platform in the food and cannabis sectors: faster and cheaper than freeze drying, with better end product quality than air drying or spray drying. EnWave currently offers two distinct commercial REV platforms:

    1. nutraREV which is a drum-based system that dehydrates organic materials quickly and at low-cost, while maintaining high levels of nutrition, taste, texture and colour; and,
    2. quantaREV which is a tray-based system used for continuous, high-volume low-temperature drying.

    More information about EnWave is available at www.enwave.net.

    EnWave Corporation
    Mr. Brent Charleton, CFA
    President and CEO

    For further information:

    Brent Charleton, CFA, President and CEO at +1 (778) 378-9616
    E-mail: bcharleton@enwave.net    

    Dan Henriques, CPA, CA, CFO at +1 (604) 835-5212
    E-mail: dhenriques@enwave.net  

    For Media Inquiries:
    Email: media@enwave.net

    Lesen Sie auch

    Safe Harbour for Forward-Looking Information Statements: This press release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures, and the expected synergies following the closing, are forward-looking statements. All third-party claims referred to in this release are not guaranteed to be accurate. All third-party references to market information in this release are not guaranteed to be accurate as the Company did not conduct the original primary research. These statements are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

    Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5beff06e-3b35-43d0 ...


    Seite 2 von 2


    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Merck cites EnWave’s REV Technology as a Faster, Viable Drying Alternative to Vial-Based Lyophilization for Vaccines and Biologics - Seite 2 VANCOUVER, British Columbia, Jan. 26, 2021 (GLOBE NEWSWIRE) - EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) announces today that Merck & Co. Inc (“Merck”) published a research paper citing EnWave’s freezeREV process as a …